Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Galderma Group has delivered a strong share price run over the past year, and the recent flow of product and deal news keeps the story in the headlines. The open question is whether the current market price is aligned with what the company's cash flows can justify on a Discounted Cash Flow (DCF) basis.

• The stock is up 33.9% over the past year, which puts real pressure on the valuation case to be backed by the future cash generation implied in that move.

• China's approval of Relfydess for frown lines, on top of growing exposure in injectable aesthetics and dermatological skincare, can influence expectations for revenue durability, profit margins and the timing of cash inflows.

• What if you looked at Galderma Group through its earnings instead? See why Galderma Group's 61.5x P/E tells a different valuation story .

The stock's next move may depend on whether the current price can be fully explained by the cash flows implied in Galderma Group's intrinsic value estimate.

If you want more than a single stock story, use a focused screen of 195 high quality undervalued stocks as a starting point for comparisons on quality and valuation.

Is Galderma Group a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model values Galderma Group based on the cash it is expected to generate for shareholders over time. Latest twelve month free cash flow sits at about US$968 million, and the DCF framework assumes this moves onto a growing path, with projected annual free cash flows stepping up into the low US$2 billion range by the early 2030s.

Those cash projections, when discounted back, point to an estimated intrinsic value that is substantially above the current share price of CHF186.70. Approval of Relfydess in China, one of the largest aesthetics markets, helps explain why the cash flow outlook in the model builds in durable demand across Galderma Group's injectable and skincare franchises, even though investors are still pricing the stock below what those projected cash flows imply. Find out what Galderma Group could be worth using our Discounted Cash Flow (DCF) estimate .

The Galderma Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Galderma Group pick up where the valuation puzzle leaves off. These scenarios spell out which assumptions on Galderma Group's future growth, profitability and earnings power would need to hold for the shares to be worth materially more or materially less than today. Where a single ratio or model gives one figure, they unpack the future that number relies on so you can watch whether it actually plays out over time on the Community page.